MINOCYCLINE HYDROCHLORIDE- minocycline hydrochloride tablet, extended release
Impax Generics
----------
HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use minocycline hydrochloride extended-release tablets safely and effectively. See full prescribing information for minocycline hydrochloride extended-release tablets.
Minocycline Hydrochloride Extended-Release Tablets for oral use Initial U.S. Approval: 1971 INDICATIONS AND USAGEMinocycline hydrochloride extended-release tablets are a tetracycline-class drug indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. (1) DOSAGE AND ADMINISTRATIONThe recommended dosage of minocycline hydrochloride extended-release tablets is approximately 1 mg/kg once daily for 12 weeks. (2) DOSAGE FORMS AND STRENGTHSExtended release tablets: 45, 90, and 135 mg (3) CONTRAINDICATIONSThis drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. (4) WARNINGS AND PRECAUTIONS
ADVERSE REACTIONSThe most commonly observed adverse reactions (incidence ≥ 5%) are headache, fatigue, dizziness, and pruritus. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact IMPAX Laboratories, Inc. at 1-800-934-6729 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS
USE IN SPECIFIC POPULATIONSSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 4/2013 |
Minocycline hydrochloride extended-release tablets are indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.
Minocycline hydrochloride extended-release tablets did not demonstrate any effect on non-inflammatory acne lesions. Safety of minocycline hydrochloride extended-release tablets has not been established beyond 12 weeks of use. This formulation of minocycline has not been evaluated in the treatment of infections [see CLINICAL STUDIES (14)].
To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, minocycline hydrochloride extended-release tablets should be used only as indicated [see WARNINGS AND PRECAUTIONS (5.11)].
The recommended dosage of minocycline hydrochloride extended-release tablets is approximately 1 mg/kg once daily for 12 weeks. Higher doses have not shown to be of additional benefit in the treatment of inflammatory lesions of acne, and may be associated with more acute vestibular side effects.
The following table shows tablet strength and body weight to achieve approximately 1 mg/kg.
Patient's Weight (lbs.) | Patient's Weight (kg) | Tablet Strength (mg) | Actual mg/kg Dose |
---|---|---|---|
99 to 109 | 45 to 49 | 45 | 1 to 0.92 |
110 to 131 | 50 to 59 | 55 | 1.10 to 0.93 |
132 to 157 | 60 to 71 | 65 | 1.08 to 0.92 |
158 to 186 | 72 to 84 | 80 | 1.11 to 0.95 |
187 to 212 | 85 to 96 | 90 | 1.06 to 0.94 |
213 to 243 | 97 to 110 | 105 | 1.08 to 0.95 |
244 to 276 | 111 to 125 | 115 | 1.04 to 0.92 |
277 to 300 | 126 to 136 | 135 | 1.07 to 0.99 |
Minocycline hydrochloride extended-release tablets may be taken with or without food [see CLINICAL PHARMACOLOGY (12)]. Ingestion of food along with minocycline hydrochloride extended-release tablets may help reduce the risk of esophageal irritation and ulceration.
In patients with renal impairment, the total dosage should be decreased by either reducing the recommended individual doses and/or by extending the time intervals between doses [see WARNINGS AND PRECAUTIONS (5.4)].
This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.
Minocycline hydrochloride extended-release tablets should not be used during pregnancy or by individuals of either gender who are attempting to conceive a child [see NONCLINICAL TOXICOLOGY (13.1) & USE IN SPECIFIC POPULATIONS (8.1)].
This adverse reaction is more common during long-term use of the drug but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED DURING TOOTH DEVELOPMENT.
Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can cause retardation of skeletal development on the developing fetus. Evidence of embryotoxicity has been noted in animals treated early in pregnancy [see USE IN SPECIFIC POPULATIONS (8.1)].
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibactieral agents, including minocycline hydrochloride extended-release tablets, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy, CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antiobiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
Post-marketing cases of serious liver injury, including irreversible drug-induced hepatitis and fulminant hepatic failure (sometimes fatal) have been reported with minocycline use in the treatment of acne.
The anti-anabolic action of the tetracyclines may cause an increase in BUN. While this is not a problem in those with normal renal function, in patients with significantly impaired function, higher serum levels of tetracycline-class drugs may lead to azotemia, hyperphosphatemia, and acidosis. If renal impairment exists, even usual oral or parenteral doses may lead to excessive systemic accumulations of the drug and possible liver toxicity. Under such conditions, lower than usual total doses are indicated, and if therapy is prolonged, serum level determinations of the drug may be advisable.
Central nervous system side effects including light-headedness, dizziness or vertigo have been reported with minocycline therapy. Patients who experience these symptoms should be cautioned about driving vehicles or using hazardous machinery while on minocycline therapy. These symptoms may disappear during therapy and usually rapidly disappear when the drug is discontinued.
Pseudotumor cerebri (benign intracranial hypertension) in adults and adolescents has been associated with the use of tetracyclines. Minocycline has been reported to cause or precipitate pseudotumor cerebri, the hallmark of which is papilledema. Clinical manifestations include headache and blurred vision. Bulging fontanels have been associated with the use of tetracyclines in infants. Although signs and symptoms of pseudotumor cerebri resolve after discontinuation of treatment, the possibility for permanent sequelae such as visual loss that may be permanent or severe exists. Patients should be questioned for visual disturbances prior to initiation of treatment with tetracyclines. If visual disturbance occurs during treatment, patients should be checked for papilledema. Concomitant use of isotretinoin and minocycline should be avoided because isotretinoin, a systemic retinoid, is also known to cause pseudotumor cerebri.
Tetracyclines have been associated with the development of autoimmune syndromes. The long-term use of minocycline in the treatment of acne has been associated with drug-induced lupus-like syndrome, autoimmune hepatitis and vasculitis. Sporadic cases of serum sickness have presented shortly after minocycline use. Symptoms may be manifested by fever, rash, arthralgia, and malaise. In symptomatic patients, liver function tests, ANA, CBC, and other appropriate tests should be performed to evaluate the patients. Use of all tetracycline-class drugs should be discontinued immediately.
Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. This has been reported rarely with minocycline. Patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using minocycline. If patients need to be outdoors while using minocycline, they should wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician.
Cases of anaphylaxis, serious skin reactions (e.g. Stevens Johnson syndrome), erythema multiforme, and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported postmarketing with minocycline use in patients with acne. DRESS syndrome consists of cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, and one or more of the following visceral complications such as: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis. Fever and lymphadenopathy may be present. In some cases, death has been reported. If this syndrome is recognized, the drug should be discontinued immediately.
Tetracycline class antibiotics are known to cause hyperpigmentation. Tetracycline therapy may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity (teeth, mucosa, alveolar bone), sclerae and heart valves. Skin and oral pigmentation has been reported to occur independently of time or amount of drug administration, whereas other tissue pigmentation has been reported to occur upon prolonged administration. Skin pigmentation includes diffuse pigmentation as well as over sites of scars or injury.
Bacterial resistance to the tetracyclines may develop in patients using minocycline hydrochloride extended-release tablets, therefore, the susceptibility of bacteria associated with infection should be considered in selecting antimicrobial therapy. Because of the potential for drug-resistant bacteria to develop during the use of minocycline hydrochloride extended-release tablets, it should be used only as indicated.
As with other antibiotic preparations, use of minocycline hydrochloride extended-release tablets may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, minocycline hydrochloride extended-release tablets should be discontinued and appropriate therapy instituted.
Because clinical trials are conducted under prescribed conditions, adverse reaction rates observed in the clinical trial may not reflect the rates observed in practice.
The following table summarizes selected adverse reactions reported in clinical trials at a rate of ≥1% for minocycline hydrochloride extended-release tablets.
Adverse Reactions | Minocycline HCl ER Tablets (1 mg/kg) N = 674 (%) | PLACEBO N = 364 (%) |
---|---|---|
At least one treatment-emergent event | 379 (56) | 197 (54) |
Headache | 152 (23) | 83 (23) |
Fatigue | 62 (9) | 24 (7) |
Dizziness | 59 (9) | 17 (5) |
Pruritus | 31 (5) | 16 (4) |
Malaise | 26 (4) | 9 (3) |
Mood alteration | 17 (3) | 9 (3) |
Somnolence | 13 (2) | 3 (1) |
Urticaria | 10 (2) | 1 (0) |
Tinnitus | 10 (2) | 5 (1) |
Arthralgia | 9 (1) | 2 (0) |
Vertigo | 8 (1) | 3 (1) |
Dry mouth | 7 (1) | 5 (1) |
Myalgia | 7 (1) | 4 (1) |
Adverse reactions that have been reported with minocycline hydrochloride use in a variety of indications include:
Preliminary studies suggest that use of minocycline may have deleterious effects on human spermatogenesis [see NONCLINICAL TOXICOLOGY (13.1)].
Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin.
The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations.
In a multi-center study to evaluate the effect of minocycline hydrochloride extended-release tablets on low dose oral contraceptives, hormone levels over one menstrual cycle with and without minocycline hydrochloride extended-release tablets 1 mg/kg once-daily were measured. Based on the results of this trial, minocycline-related changes in estradiol, progestinic hormone, FSH and LH plasma levels, of breakthrough bleeding, or of contraceptive failure, can not be ruled out. To avoid contraceptive failure, female patients are advised to use a second form of contraceptive during treatment with minocycline.
Teratogenic Effects: Pregnancy category D [see WARNINGS AND PRECAUTIONS (5.1)]
Minocycline hydrochloride extended-release tablets should not be used during pregnancy. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and stop treatment immediately.
There are no adequate and well-controlled studies on the use of minocycline in pregnant women. Minocycline, like other tetracycline-class drugs, crosses the placenta and may cause fetal harm when administered to a pregnant woman.
Rare spontaneous reports of congenital anomalies including limb reduction have been reported with minocycline use in pregnancy in post-marketing experience. Only limited information is available regarding these reports; therefore, no conclusion on causal association can be established.
Minocycline induced skeletal malformations (bent limb bones) in fetuses when administered to pregnant rats and rabbits in doses of 30 mg/kg/day and 100 mg/kg/day, respectively, (resulting in approximately 3 times and 2 times, respectively, the systemic exposure to minocycline observed in patients as a result of use of minocycline hydrochloride extended-release tablets). Reduced mean fetal body weight was observed in studies in which minocycline was administered to pregnant rats at a dose of 10 mg/kg/day (which resulted in approximately the same level of systemic exposure to minocycline as that observed in patients who use minocycline hydrochloride extended-release tablets).
Minocycline was assessed for effects on peri- and post-natal development of rats in a study that involved oral administration to pregnant rats from day 6 of gestation through the period of lactation (postpartum day 20), at dosages of 5, 10, or 50 mg/kg/day. In this study, body weight gain was significantly reduced in pregnant females that received 50 mg/kg/day (resulting in approximately 2.5 times the systemic exposure to minocycline observed in patients as a result of use of minocycline hydrochloride extended-release tablets). No effects of treatment on the duration of the gestation period or the number of live pups born per litter were observed. Gross external anomalies observed in F1 pups (offspring of animals that received minocycline) included reduced body size, improperly rotated forelimbs, and reduced size of extremities. No effects were observed on the physical development, behavior, learning ability, or reproduction of F1 pups, and there was no effect on gross appearance of F2 pups (offspring of F1 animals).
Tetracycline-class antibiotics are excreted in human milk. Because of the potential for serious adverse effects on bone and tooth development in nursing infants from the tetracycline-class antibiotics, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother [see WARNINGS AND PRECAUTIONS (5.1)].
Minocycline hydrochloride extended-release tablets are indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years and older.
Safety and effectiveness in pediatric patients below the age of 12 has not been established.
Use of tetracycline-class antibiotics below the age of 8 is not recommended due to the potential for tooth discoloration [see WARNINGS AND PRECAUTIONS (5.1)].
Clinical studies of minocycline hydrochloride extended-release tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy.
In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Minocycline is not removed in significant quantities by hemodialysis or peritoneal dialysis.
Minocycline hydrochloride, a semi synthetic derivative of tetracycline, is [4S-(4α,4aα,5aα,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide mono hydrochloride. The structural formula is represented below:
C 23H27N3O7•HCl | M. W. 493.95 |
Minocycline hydrochloride extended-release tablets for oral administration contain minocycline hydrochloride USP equivalent to 45 mg, 90 mg, or 135 mg of minocycline. In addition, 45 mg, 90 mg, and 135 mg tablets contain the following inactive ingredients: lactose monohydrate, hypromellose, magnesium stearate, titanium dioxide, triacetin, polydextrose, polyethylene glycol, iron oxide yellow (90 mg only), and red iron oxide (135 mg only).
The mechanism of action of minocycline hydrochloride extended-release tablets for the treatment of acne is unknown.
The pharmacodynamics of minocycline hydrochloride extended-release tablets for the treatment of acne are unknown.
Minocycline hydrochloride extended-release tablets are not bioequivalent to non-modified release minocycline products. Based on pharmacokinetic studies in healthy adults, minocycline hydrochloride extended-release tablets produce a delayed Tmax at 3.5 to 4 hours as compared to a non-modified release reference minocycline product (Tmax at 2.25 to 3 hours). At steady-state (Day 6), the mean AUC(0 to 24) and Cmax were 33.32 mcg×hr/mL and 2.63 mcg/mL for minocycline hydrochloride extended-release tablets and 46.35 mcg×hr/mL and 2.92 mcg/mL for minocycline hydrochloride capsules, respectively. These parameters are based on dose adjusted to 135 mg per day for both products.
A single-dose, four-way crossover study demonstrated that minocycline hydrochloride extended-release tablets used in the study (45 mg, 90 mg, 135 mg) exhibited dose-proportional pharmacokinetics.
When minocycline hydrochloride extended-release tablets were administered concomitantly with a meal that included dairy products, the extent and timing of absorption of minocycline did not differ from that of administration under fasting conditions.
Minocycline is lipid soluble and distributes into the skin and sebum.
Carcinogenesis–Long-term animal studies have not been performed to evaluate the carcinogenic potential of minocycline. A structurally related compound, oxytetracycline, was found to produce adrenal and pituitary tumors in rats.
Mutagenesis–Minocycline was not mutagenic in vitro in a bacterial reverse mutation assay (Ames test) or CHO/HGPRT mammalian cell assay in the presence or absence of metabolic activation. Minocycline was not clastogenic in vitro using human peripheral blood lymphocytes or in vivo in a mouse micronucleus test.
Impairment of Fertility–Male and female reproductive performance in rats was unaffected by oral doses of minocycline of up to 300 mg/ kg/day (which resulted in up to approximately 40 times the level of systemic exposure to minocycline observed in patients as a result of use of minocycline hydrochloride extended-release tablets). However, oral administration of 100 or 300 mg/kg/day of minocycline to male rats (resulting in approximately 15 to 40 times the level of systemic exposure to minocycline observed in patients as a result of use of minocycline hydrochloride extended-release tablets) adversely affected spermatogenesis. Effects observed at 300 mg/kg/day included a reduced number of sperm cells per gram of epididymis, an apparent reduction in the percentage of sperm that were motile, and (at 100 and 300 mg/kg/day) increased numbers of morphologically abnormal sperm cells. Morphological abnormalities observed in sperm samples included absent heads, misshapen heads, and abnormal flagella.
Limited human studies suggest that minocycline may have a deleterious effect on spermatogenesis.
Minocycline hydrochloride extended-release tablets should not be used by individuals of either gender who are attempting to conceive a child.
The safety and efficacy of minocycline hydrochloride extended-release tablets in the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris was assessed in two 12-week, multi-center, randomized, double-blind, placebo-controlled, studies in subjects ≥ 12 years. The mean age of subjects was 20 years and subjects were from the following racial groups: White (73%), Hispanic (13%), Black (11%), Asian/ Pacific Islander (2%), and Other (2%).
In two efficacy and safety trials, a total of 924 subjects with non-nodular moderate to severe acne vulgaris received minocycline hydrochloride extended-release tablets or placebo for a total of 12 weeks, according to the following dose assignments.
Subject's Weight (lbs) | Subject's Weight (kg) | Available Caplet Strength (mg) | Actual mg/kg Dose |
---|---|---|---|
99 to 131 | 45 to 59 | 45 | 1 to 0.76 |
132 to 199 | 60 to 90 | 90 | 1.5 to 1 |
200 to 300 | 91 to 136 | 135 | 1.48 to 0.99 |
The two primary efficacy endpoints were:
Study 1 | Study 2 | |||
---|---|---|---|---|
Minocycline HCl ER Tablets (1 mg/kg) | Placebo | Minocycline HCl ER Tablets (1 mg/kg) | Placebo | |
N = 300 | N = 151 | N = 315 | N = 158 | |
|
||||
Mean Percent Improvement in Inflammatory Lesions | 43.1% | 31.7% | 45.8% | 30.8% |
No. (%) of Subjects Clear or Almost Clear on the EGSA* | 52 (17.3%) | 12 (7.9%) | 50 (15.9%) | 15 (9.5%) |
Minocycline hydrochloride extended-release tablets did not demonstrate any effect on non-inflammatory lesions (benefit or worsening).
Minocycline hydrochloride extended-release tablets are supplied as follows.
Minocycline hydrochloride extended-release tablets, 45 mg – white to off-white, film-coated oval tablets, debossed with "H21" on one side and plain on the other side.
Bottles of 30 | NDC 0115-1245-08 |
Bottles of 90 | NDC 0115-1245-10 |
Bottles of 100 | NDC 0115-1245-01 |
Bottles of 500 | NDC 0115-1245-02 |
Bottles of 1000 | NDC 0115-1245-03 |
Minocycline hydrochloride extended-release tablets, 90 mg – yellow, film-coated oval tablets, debossed with "H22" on one side and plain on the other side.
Bottles of 30 | NDC 0115-1246-08 |
Bottles of 90 | NDC 0115-1246-10 |
Bottles of 100 | NDC 0115-1246-01 |
Bottles of 500 | NDC 0115-1246-02 |
Bottles of 1000 | NDC 0115-1246-03 |
Minocycline hydrochloride extended-release tablets, 135 mg – reddish-brown, film-coated oval tablets, debossed with "H23" on one side and plain on the other side.
Bottles of 30 | NDC 0115-1247-08 |
Bottles of 90 | NDC 0115-1247-10 |
Bottles of 100 | NDC 0115-1247-01 |
Bottles of 500 | NDC 0115-1247-02 |
Bottles of 1000 | NDC 0115-1247-03 |
[See FDA-Approved Patient Labeling (Patient Information)]
Patients taking minocycline hydrochloride extended-release tablets should receive the following information and instructions:
Rx only
Manufactured by:
IMPAX Laboratories, Inc.
Hayward, CA 94544 USA
Distributed by:
Global Pharmaceuticals
Division of IMPAX Laboratories, Inc.
Philadelphia, PA 19124 USA
Rev. 11/2011
822-08
PHARMACIST – DETACH HERE AND GIVE LEAFLET TO PATIENT.
Patient Information
Minocycline Hydrochloride Extended-Release Tablets
(minocycline HCl, USP)
Read this Patient Information leaflet that comes with minocycline hydrochloride extended-release tablets before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your condition or treatment.
What are minocycline hydrochloride extended-release tablets?
Minocycline hydrochloride is a tetracycline class drug. Minocycline hydrochloride extended-release tablets is a prescription medicine used to treat pimples and red bumps (non-nodular inflammatory lesions) that happen with moderate to severe acne vulgaris in people 12 years and older. Minocycline hydrochloride extended-release tablets are not effective for acne that is not red-looking (this means acne that is not inflammatory).
It is not known if minocycline hydrochloride extended-release tablets are:
Who should not take minocycline hydrochloride extended-release tablets?
Do not take minocycline hydrochloride extended-release tablets if you are allergic to tetracycline class drugs. Ask your doctor or pharmacist for a list of these medicines if you are not sure.
What should I tell my doctor before taking minocycline hydrochloride extended-release tablets?
Before you take minocycline hydrochloride extended-release tablets, tell your doctor if you:
Tell your doctor about all the other medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements. Minocycline hydrochloride extended-release tablets may affect the way other medicines work, and other medicines may affect how minocycline hydrochloride extended-release tablets work.
Especially tell your doctor if you take:
Ask your doctor or pharmacist if you are not sure if your medicine is one that is listed above.
Know the medicines you take. Keep a list of them to show your doctor and pharmacist.
How should I take minocycline hydrochloride extended-release tablets?
If you take too much minocycline hydrochloride extended-release tablets, call your doctor or poison control center right away. Your doctor may do blood tests to check you for side effects during treatment with minocycline hydrochloride extended-release tablets.
What should I avoid while taking minocycline hydrochloride extended-release tablets?
What are possible side effects of minocycline hydrochloride extended-release tablets?
Minocycline hydrochloride extended-release tablets may cause serious side effects, including:
The most common side effects of minocycline hydrochloride extended-release tablets include:
Call your doctor if you have a side effect that bothers you or that does not go away. Your doctor may do tests to check you for side effects during treatment with minocycline hydrochloride extended-release tablets.
These are not all the side effects with minocycline hydrochloride extended-release tablets. Ask your doctor or pharmacist for more information.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Impax Laboratories, Inc. at 1-800-934-6729.
How should I store minocycline hydrochloride extended-release tablets?
Keep minocycline hydrochloride extended-release tablets and all medicines out of the reach of children.
General information about minocycline hydrochloride extended-release tablets
Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet. Do not use minocycline hydrochloride extended-release tablets for a condition for which it was not prescribed. Do not give minocycline hydrochloride extended-release tablets to other people, even if they have the same symptoms you have. It may harm them.
This Patient Information leaflet summarizes the most important information about minocycline hydrochloride extended-release tablets. If you would like more information, talk to your doctor. You can ask your doctor or pharmacist for information about minocycline hydrochloride extended-release tablets that is written for health professionals.
What are the ingredients in minocycline hydrochloride extended-release tablets?
Active Ingredient: minocycline HCl USP.
Inactive Ingredients: lactose monohydrate, hypromellose, magnesium stearate, titanium dioxide, triacetin, polydextrose, polyethylene glycol, iron oxide yellow (90 mg only), and red iron oxide (135 mg only).
Manufactured by:
IMPAX Laboratories, Inc.
Hayward, CA 94544 USA
Distributed by:
Global Pharmaceuticals
Division of IMPAX Laboratories, Inc.
Philadelphia, PA 19124 USA
Rev. 11/2011
822-08
PRINCIPAL DISPLAY PANEL - 45 mg Tablet Bottle Label
GLOBAL®
NDC 0115-1245-08
Minocycline
Hydrochloride
Extended-Release Tablets
45 mg
Rx only
30 TABLETS
MINOCYCLINE HYDROCHLORIDE
minocycline hydrochloride tablet, extended release |
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
MINOCYCLINE HYDROCHLORIDE
minocycline hydrochloride tablet, extended release |
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
MINOCYCLINE HYDROCHLORIDE
minocycline hydrochloride tablet, extended release |
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
Labeler - Impax Generics (079832487) |